0
Blueprint Medicines Corp Banner Image

Blueprint Medicines Corp

  • Ticker BPMC
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Blueprint Medicines Corp Logo Image
  • 501-1000 Employees
  • Based in Cambridge, Massachusetts
Blueprint Medicines Corporation, a biopharmaceutical company, focuses on the development of the highly selective kinase inhibitors for genomically defined cancer subsets. The company’s lead drug candidates include BLU-285, which targets KIT Exon 17 and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorderMore of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor, as well as targets the KIT D816V mutation; and BLU-554, an orally available, potent, selective, and irreversible inhibitor, which targets FGFR4.
Blueprint Medicines Corp

Most Recent Responsibility Report

Blueprint Medicines Corp
MOST RECENT 2022 Corporate Responsibility Report

Blueprint Medicines Corp does not currently have any hardcopy reports on ResponsibilityReports.com. Click the button below to request a report when hardcopies become available.

Request Information

Archived Responsibility Reports

Our service enables potential investors to review the most recent and archived Blueprint Medicines Corp Sustainability Report, Blueprint Medicines Corp Corporate Social Responsibility Report, Blueprint Medicines Corp CSR Report, Blueprint Medicines Corp Corporate Responsibility, Blueprint Medicines Corp CR Report, Blueprint Medicines Corp Citizenship Report, Blueprint Medicines Corp ESG Report, and Blueprint Medicines Corp Environmental Report online.
Blueprint Medicines Corp Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!